Tumor Microenvironmental Regulation of CAR T-Cell Therapy in High Risk Medulloblastoma - PubMed
2 hours ago
- #tumor microenvironment
- #CAR T-cell therapy
- #medulloblastoma
- B7-H3-targeted CAR T-cell therapy shows initial safety and antitumor activity in pediatric brain tumors but lacks durability.
- In Group 3 medulloblastoma, myeloid cells in the tumor microenvironment regulate T-cell function via the TLR7/8 pathway.
- Dual-costimulatory CAR designs with CD28 and 4-1BB outperform single-costimulation in immunocompetent models, enhancing cytotoxicity and persistence.
- Nanoparticle-delivered TLR7/8 agonist Resiquimod activates myeloid cells and reduces suppressive populations, boosting CAR T-cell efficacy.
- Combining optimized CAR architecture with TLR7/8-mediated myeloid reprogramming improves therapeutic outcomes in high-risk medulloblastoma.